Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Q4 2024 Earnings Conference Call
On March 6, 2025, Arcturus Therapeutics Holdings Inc. held its Fourth Quarter and Full Year 2024 Earnings Conference Call. The call was led by Neda Safarzadeh, Vice President and Head of Investor Relations, Joe Payne, President and Chief Executive Officer, Director of the Board, Andy Sassine, Chief Financial Officer, Pad Chivukula, Chief Scientific Officer and Chief Operating Officer. The conference call was attended by several analysts, including Lili Nsongo from Leerink, Yasmeen Rahimi from Piper Sandler, Evan Wang from Guggenheim, Myles Minter from William Blair, Joohwan Kim from Canaccord, Pete Stavropoulos from Cantor, Tom Shrader from BTIG, Thomas Yip from HCW, and Yanan Zhu from Wells Fargo. Yale Jen from Laidlaw & Company was also present.
Company Participants
- Neda Safarzadeh – Vice President, Head of Investor Relations
- Joe Payne – President and Chief Executive Officer, Director of the Board
- Andy Sassine – Chief Financial Officer
- Pad Chivukula – Chief Scientific Officer and Chief Operating Officer
Conference Call Participants
- Lili Nsongo – Leerink
- Yasmeen Rahimi – Piper Sandler
- Evan Wang – Guggenheim
- Myles Minter – William Blair
- Joohwan Kim – Canaccord
- Pete Stavropoulos – Cantor
- Tom Shrader – BTIG
- Thomas Yip – HCW
- Yanan Zhu – Wells Fargo
- Yale Jen – Laidlaw & Company
During the call, the Arcturus Therapeutics executives provided updates on the company’s financial results, ongoing research and development programs, and future plans. Payne highlighted the company’s progress in developing its LUNAR lipid nanoparticle (LNP) technology, which is used to deliver messenger RNA (mRNA) therapeutics and vaccines. Chivukula discussed the potential of ARCT-021, a LUNAR-encoded mRNA therapeutic for the treatment of cystic fibrosis, and ARCT-056, a LUNAR-encoded mRNA therapeutic for the treatment of peripheral artery disease. Sassine discussed the company’s financial performance for the quarter and the full year, reporting a net loss of $149.3 million for the quarter and $555.5 million for the year.
Impact on Individuals
The developments at Arcturus Therapeutics could have a significant impact on individuals with cystic fibrosis and peripheral artery disease. ARCT-021, the LUNAR-encoded mRNA therapeutic for the treatment of cystic fibrosis, has the potential to provide a meaningful improvement in lung function and overall health for patients with this debilitating disease. ARCT-056, on the other hand, could offer a new treatment option for peripheral artery disease, a condition that affects the circulation in the legs and can lead to pain, cramping, and even limb loss in severe cases.
Impact on the World
The progress made by Arcturus Therapeutics in the development of its LNP technology and its potential applications in mRNA therapeutics and vaccines could have a profound impact on the world. The COVID-19 pandemic has highlighted the importance of rapid and effective vaccine development, and Arcturus’ LNP technology could play a key role in future vaccines. Additionally, the potential applications of mRNA therapeutics extend far beyond the current focus on vaccines, and could offer new treatments for a wide range of diseases, from genetic disorders to cancer.
Conclusion
Arcturus Therapeutics’ Fourth Quarter and Full Year 2024 Earnings Conference Call provided insight into the company’s financial performance and ongoing research and development efforts. The potential applications of the company’s LUNAR lipid nanoparticle technology in mRNA therapeutics and vaccines could have a significant impact on individuals with conditions such as cystic fibrosis and peripheral artery disease, as well as on the world as a whole, particularly in the area of vaccine development. As the company continues to make progress in these areas, investors and analysts will be closely watching for updates on its pipeline and financial performance.
